bcl10 mutations Search Results


bcl10 untagged cdna  (OriGene)
93
OriGene bcl10 untagged cdna
Bcl10 Untagged Cdna, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bcl10+mutations/pmc03174537-204-26-33?v=OriGene
Average 93 stars, based on 1 article reviews
bcl10 untagged cdna - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
mouse monoclonal antibody to bcl10  (Novus Biologicals)
90
Novus Biologicals mouse monoclonal antibody to bcl10
Effects of blocking antibody for TLR4 on CGN-induced increases in IL-8 and <t>Bcl10.</t> a, IL-8 was measured following exposure of NCM460 cells to λCGN (1 and 10 μg/ml for 24 h) following pretreatment with TLR4 blocking antibody (HTA-125) at concentrations of 10 and 20 μg/ml for 2 h. A dose-response effect is seen, with a reduced concentration of IL-8 in relation to a higher concentration of TLR4 blocking antibody. IL-8 in spent media was measured by ELISA and is expressed in pg/mg cell protein. Declines in IL-8 are statistically significant (*, p < 0.001). b, Bcl10 in the cell lysate was measured under conditions similar to those in A, with λCGN (1 μg/ml) and TLR4 antibody (10 μg/ml). An 80% decline in the Bcl10 protein occurred (***, p < 0.001).
Mouse Monoclonal Antibody To Bcl10, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bcl10+mutations/pmc02447641-81-7-12?v=Novus+Biologicals
Average 90 stars, based on 1 article reviews
mouse monoclonal antibody to bcl10 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
mutant bcl10  (Thermo Fisher)
99
Thermo Fisher mutant bcl10
Effects of blocking antibody for TLR4 on CGN-induced increases in IL-8 and <t>Bcl10.</t> a, IL-8 was measured following exposure of NCM460 cells to λCGN (1 and 10 μg/ml for 24 h) following pretreatment with TLR4 blocking antibody (HTA-125) at concentrations of 10 and 20 μg/ml for 2 h. A dose-response effect is seen, with a reduced concentration of IL-8 in relation to a higher concentration of TLR4 blocking antibody. IL-8 in spent media was measured by ELISA and is expressed in pg/mg cell protein. Declines in IL-8 are statistically significant (*, p < 0.001). b, Bcl10 in the cell lysate was measured under conditions similar to those in A, with λCGN (1 μg/ml) and TLR4 antibody (10 μg/ml). An 80% decline in the Bcl10 protein occurred (***, p < 0.001).
Mutant Bcl10, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bcl10+mutations/pmc01951946-143-15-23?v=Thermo+Fisher
Average 99 stars, based on 1 article reviews
mutant bcl10 - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier

Image Search Results


Effects of blocking antibody for TLR4 on CGN-induced increases in IL-8 and Bcl10. a, IL-8 was measured following exposure of NCM460 cells to λCGN (1 and 10 μg/ml for 24 h) following pretreatment with TLR4 blocking antibody (HTA-125) at concentrations of 10 and 20 μg/ml for 2 h. A dose-response effect is seen, with a reduced concentration of IL-8 in relation to a higher concentration of TLR4 blocking antibody. IL-8 in spent media was measured by ELISA and is expressed in pg/mg cell protein. Declines in IL-8 are statistically significant (*, p < 0.001). b, Bcl10 in the cell lysate was measured under conditions similar to those in A, with λCGN (1 μg/ml) and TLR4 antibody (10 μg/ml). An 80% decline in the Bcl10 protein occurred (***, p < 0.001).

Journal:

Article Title: Toll-like Receptor 4 Mediates Induction of the Bcl10-NF?B-Interleukin-8 Inflammatory Pathway by Carrageenan in Human Intestinal Epithelial Cells *

doi: 10.1074/jbc.M708833200

Figure Lengend Snippet: Effects of blocking antibody for TLR4 on CGN-induced increases in IL-8 and Bcl10. a, IL-8 was measured following exposure of NCM460 cells to λCGN (1 and 10 μg/ml for 24 h) following pretreatment with TLR4 blocking antibody (HTA-125) at concentrations of 10 and 20 μg/ml for 2 h. A dose-response effect is seen, with a reduced concentration of IL-8 in relation to a higher concentration of TLR4 blocking antibody. IL-8 in spent media was measured by ELISA and is expressed in pg/mg cell protein. Declines in IL-8 are statistically significant (*, p < 0.001). b, Bcl10 in the cell lysate was measured under conditions similar to those in A, with λCGN (1 μg/ml) and TLR4 antibody (10 μg/ml). An 80% decline in the Bcl10 protein occurred (***, p < 0.001).

Article Snippet: Immobilized Bcl10 molecules were detected by a mouse monoclonal antibody to Bcl10 (Novus Biologicals, Littleton, CO) and goat anti-mouse IgG-horseradish peroxidase complex (Santa Cruz Biotechnology, Santa Cruz, CA).

Techniques: Blocking Assay, Concentration Assay, Enzyme-linked Immunosorbent Assay

CGN-induced increase in Bcl10 and IL-8 is MyD88-dependent. a, MyD88 was silenced by insertion of a dominant-negative plasmid for MyD88. CGN-induced IL-8 increase declined 78% from 1274 ± 117 to 776 ± 41 pg/ml. This finding suggests that there is an alternative, minor pathway of CGN-induced IL-8 activation that is not mediated by TLR-4-Bcl10. b, similarly, following knockdown of MyD88, CGN-induced increase in Bl10, as determined by ELISA, was completely inhibited, declining from a peak of 3.83 ± 0.17 to a base line of 1.21 ± 0.08 (***, p < 0.001, one-way ANOVA with Tukey-Kramer post-test for multiple comparisons). Cn, control.

Journal:

Article Title: Toll-like Receptor 4 Mediates Induction of the Bcl10-NF?B-Interleukin-8 Inflammatory Pathway by Carrageenan in Human Intestinal Epithelial Cells *

doi: 10.1074/jbc.M708833200

Figure Lengend Snippet: CGN-induced increase in Bcl10 and IL-8 is MyD88-dependent. a, MyD88 was silenced by insertion of a dominant-negative plasmid for MyD88. CGN-induced IL-8 increase declined 78% from 1274 ± 117 to 776 ± 41 pg/ml. This finding suggests that there is an alternative, minor pathway of CGN-induced IL-8 activation that is not mediated by TLR-4-Bcl10. b, similarly, following knockdown of MyD88, CGN-induced increase in Bl10, as determined by ELISA, was completely inhibited, declining from a peak of 3.83 ± 0.17 to a base line of 1.21 ± 0.08 (***, p < 0.001, one-way ANOVA with Tukey-Kramer post-test for multiple comparisons). Cn, control.

Article Snippet: Immobilized Bcl10 molecules were detected by a mouse monoclonal antibody to Bcl10 (Novus Biologicals, Littleton, CO) and goat anti-mouse IgG-horseradish peroxidase complex (Santa Cruz Biotechnology, Santa Cruz, CA).

Techniques: Dominant Negative Mutation, Plasmid Preparation, Activation Assay, Knockdown, Enzyme-linked Immunosorbent Assay, Control

Inhibition of IRAK reduces CGN-associated increases in Bcl10 and IL-8. a, marked decline in IL-8 of the spent media follows treatment with IRAK1/4 inhibitor. b, similarly, a marked decline in Bcl10 protein content follows pretreatment with IRAK 1/4 inhibitor, placing Bcl10 downstream of IRAK in the cascade induced by CGN exposure. Cn, control; CGN, λCGN (1 μg/ml for 24 h); I, IRAK inhibitor. ***, p < 0.001 (one-way ANOVA with Tukey-Kramer post-test for multiple comparisons).

Journal:

Article Title: Toll-like Receptor 4 Mediates Induction of the Bcl10-NF?B-Interleukin-8 Inflammatory Pathway by Carrageenan in Human Intestinal Epithelial Cells *

doi: 10.1074/jbc.M708833200

Figure Lengend Snippet: Inhibition of IRAK reduces CGN-associated increases in Bcl10 and IL-8. a, marked decline in IL-8 of the spent media follows treatment with IRAK1/4 inhibitor. b, similarly, a marked decline in Bcl10 protein content follows pretreatment with IRAK 1/4 inhibitor, placing Bcl10 downstream of IRAK in the cascade induced by CGN exposure. Cn, control; CGN, λCGN (1 μg/ml for 24 h); I, IRAK inhibitor. ***, p < 0.001 (one-way ANOVA with Tukey-Kramer post-test for multiple comparisons).

Article Snippet: Immobilized Bcl10 molecules were detected by a mouse monoclonal antibody to Bcl10 (Novus Biologicals, Littleton, CO) and goat anti-mouse IgG-horseradish peroxidase complex (Santa Cruz Biotechnology, Santa Cruz, CA).

Techniques: Inhibition, Control